Prior to changing pulmonary hypertension medications from bosentan to macitentan, bosentan could have increased the hepatic metabolism of warfarin by inducing CYP2C9 and CYP3A4 activity and decreasing its anticoagulant effects. The gene discussed is CYP2C9; the disease is pulmonary hypertension.